New York, NY (PRWEB) August 27, 2013
DND Technologies (http://www.dndtechnologies.com) has acquired all the inventory, other assets and the exclusive rights to distribute a pharmaceutical line of products in the United States, Canada and Europe. Rebranded by DNDT, the inventory of products includes Bioassaygen Gel, Bioassaygen Cosmetic Mask, Bioassaygen Bio-Skin, and Bioassaygen Delivery Gel, all of which will henceforth be manufactured and distributed by DNDT under the “Bioassaygen” brand of products. A contract-manufacturer for the product has already been identified in Europe, and sale and distribution arrangements are currently being made in several European countries.
- Bioassaygen Gel is a cosmeceutical that, when applied directly to the skin, reduces wrinkles and promotes natural skin re-genesis.
- Bioassaygen Cosmetic Mask is a stabilizing platform for the sustained use of Bioassaygen Gel. It is used mainly for vanity applications.
- Bioassaygen Bio-Skin is a scientifically developed Skin Replacement Bandage.
- Bioassaygen Delivery Gel (a serum) is a biologically-active catalyst that, when applied, creates an environment which accelerates natural skin re-genesis. Generally used in conjunction with Bioassaygen Bio-Skin.
The patented Skin Replacement Bandage and Delivery Gel products are designed to replace natural skin that may have been lost due to burns, frostbite, pressure sores, etc. The Bio-Skin technology is designed to replace traditional skin grafting by using synthetically-created skin in lieu of natural skin.
The patented Cosmetic Mask formula, when applied to the epidermis, also creates an environment that accelerates the re-genesis of natural skin cells, Benefits of the Cosmetic Mask include reduction of wrinkles, diminishment of enlarged pores, minimization of dark circles, prevention of acne, and more. Bioassaygen, now the patent owner, plans on developing additional products to augment the current line of cosmetics.
Bioassaygen Bio-Skin is a skin product that was developed in Russia for military applications in the event of chemical or nuclear war. There have been numerous cases of successful skin replacement using Bioassaygen technology, and the Russian Ministry of Health (the equivalent of the U.S. FDA) approved Bioassaygen Bio- Skin products.
The rebranding and re-launching of the products has already garnered substantial interest from European cosmetics wholesale distribution and retail firms. However, DNDT plans to solidify its manufacturing base before undertaking arrangements that may require large, constant and reliable supply of the products.
In the United States and Canada, the company has already undertaken initial discussions with direct and Multi-Level-Marketing companies as a possible means of introducing Bioassaygen Gel and the Bioassaygen Face Mask via the media of short and long form national infomercials, and through already existing Multi-Level Marketing sales networks, with a view to an ultimate goal of having the products routinely distributed by major cosmetics supply companies.
Discussions are also underway for the distribution of the products in Eastern Europe. There is also considerable official interest from some war-zone countries in the Middle East and Africa in the Bioassaygen Bio-Skin product so the company is examining the possibility of acquiring distributive rights there also.
Management made this acquisition with a collateralized financing guaranteed from a corporate shareholder. Management plans to raise additional funds to provide working capital for operations and to finance future growth. Management believes these efforts will generate sufficient cash flows from future operations to pay the Company's obligations and realize excellent benefits to shareholders. A website for the Bioassaygen product line will be launched in the coming weeks, with wholesale and retail e-commerce capabilities added shortly after.
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," “estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.